Benitec Biopharma Inc.

NASDAQ:BNTC

Biotechnology

Healthcare
$8.15 +3.05%

+$0.36 today

Market cap
$284.35M
Beta
0.28
P/E (TTM)
-12.3
EPS (TTM)
-$0.99
52W Low $9.85High $16.76

Volume 0.18M

Average 0.11M

BNTC EBITDA Margin

EBITDA as a percentage of revenue.

Benitec Biopharma Inc.NASDAQ: BNTC

EBITDA Margin · Q3 FY2026 · quarter ended Mar 2026

EBITDA Margin not reported for Q3 FY2026

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
—— QoQ
Last fiscal yearJun 2025
—— YoY
LTMMar 2026
—— YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3 years———
5 years——
10 years——

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2023
-24933.3%
Year-over-year change
-571.7pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How BNTC compares with its peers on the latest reported figures

BNTC Competitors Peer median
EBITDA Margin for BNTC and competitors
Company Period LTM level YoY 3-year change
XOMAXOMA Royalty Corp.LTM Mar 2026138.4% +176.9 pp+371.2 pp
AUTLAutolus Therapeutics plcLTM Mar 2026-249.3% +2401.7 pp+1803.8 pp
LCTXLineage Cell Therapeutics, Inc.LTM Mar 2026-291.9% -129.0 pp-296.2 pp
PRTCPureTech Health plcFY2025-1326.5% -2100.8 pp+7712.4 pp
OCGNOcugen, Inc.LTM Mar 2026-1437.5% -246.2 pp+2103.9 pp
QSIQuantum-Si incorporatedLTM Mar 2026-5352.8% -2558.8 pp—
BNTCBenitec Biopharma Inc.FY2025— ——
SLDBSolid Biosciences Inc.FY2025— ——
NGNENeurogene Inc.FY2025— ——
GALTGalectin Therapeutics Inc.FY2025— ——
Peer median (excluding BNTC) -809.2%-187.6 pp+1803.8 pp

Competitors are the stored peer set for BNTC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Jun 2021
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
Revenue59K73K75K00
Cost of Revenue123K9K0343K0
Gross Profit(64K)64K75K(343K)(396K)
Gross Margin-108.5%87.7%100.0%——
Research & Development7.02M11.27M12.77M15.61M18.33M
Selling, General & Admin6.51M6.65M6.38M6.99M23.43M
Operating Expenses13.53M17.92M19.16M22.49M41.77M
Depreciation & Amortization424K392K381K343K396K
EBITDA(13.45M)(17.78M)(18.7M)(22.15M)(41.37M)
EBITDA Margin-22800.0%-24361.6%-24933.3%——
Operating Income(13.6M)(17.85M)(19.08M)(22.49M)(41.77M)
Operating Margin-23044.1%-24457.5%-25441.3%——
Interest Income000904K0
Interest Expense6K32K33K00
Other Income / Expenses(286K)(354K)(481K)739K3.85M
Income Before Tax(13.88M)(18.21M)(19.56M)(21.75M)(37.92M)
Pre-Tax Margin-23528.8%-24942.5%-26082.7%——
Income Tax Expense00000
Net Income(13.88M)(18.21M)(19.56M)(21.75M)(37.92M)
Net Margin-23528.8%-24942.5%-26082.7%——
EPS (Basic)(27.27)(19.31)(14.12)(2.68)(1.05)
EPS (Diluted)(27.27)(19.31)(14.12)(2.68)(1.05)
Weighted Avg Shares1.01M1.92M1.39M10.26M36.21M
Weighted Avg Shares (Diluted)1.01M1.92M1.39M10.28M36.21M

Benitec Biopharma Inc.

NASDAQ:BNTC

Intrinsic Alpha fair value

Locked

Current Price

$8.15

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.